Compensation for the UK infected-blood scandal still faces delays and gaps

The Infected Blood Inquiry’s final report exposed massive failures that led to thousands contracting HIV and hepatitis from contaminated blood products in the UK. Since then, the Infected Blood Compensation Authority has paid substantial sums, and on 1 October it rolled out a fourth regulatory package that improves recognition for those infected as children, enhances provisions for hepatitis patients, and raises awards for families of the deceased.

Despite these steps, the compensation framework is still evolving, with many victims and families remaining outside the active claims process and facing uncertainty over supplementary claims that could address the most severe losses. Sir Brian Langstaff’s Additional Report highlighted the distress caused by the slow pace of payouts, noting that legal assistance is often essential due to the scheme’s complexity. A further milestone is the planned transfer of Scottish support payments to the IBCA in February 2027, which must be managed without disrupting existing benefits. Overall, the success of the scheme will be judged by whether every affected individual receives fair compensation without further delay.